Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), retaining the price target of $7.50. Discover outperforming stocks and invest smarter ...

This page features the latest news about the Kyverna Therapeutics stock. First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med Two ...

Ami Fadia, an analyst from Needham, maintained the Buy rating on Axsome Therapeutics (AXSM – Research Report). The associated price target remains the same with $133.00. Discover outperforming ...

The newly formed company will be named Decoy Therapeutics. This proposed transaction is expected to facilitate multiple value-creating inflection points with Decoy’s pipeline of peptide ...

CAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced positive results from ...

Investing.com - Omega Therapeutics (NASDAQ: OMGA) reported third quarter EPS of $-0.300, $0.02 worse than the analyst estimate of $-0.280. Revenue for the quarter came in at... ByInvesting.com ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by biotech doyen John Maraganore, and additional cash for Purespring ...

Dyne Therapeutics Inc.-3.65% $1.62B ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.